​Kyle LaHucik covers the financial underpinnings of the drug development industry for Endpoints News. He breaks news on biotech financing rounds, M&A deals, IPO planning and other business development moves that push the industry forward. He frequently covers the China biotech ecosystem and its growing role in the global industry. A graduate of the University of Missouri School of Journalism, Kyle joined Endpoints in March 2022 after reporting for other publications. Outside of work, catch him on the Chicago lakefront path, where he coaches a local high school cross country and track team, trains for marathons and bikes for fun.